Retinal Dystrophy Clinical Trials

8 recruitingLast updated: July 25, 2026

There are 8 actively recruiting retinal dystrophy clinical trials across 3 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3. Top locations include Beijing, Beijing Municipality, China, Shanghai, Shanghai Municipality, China, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Retinal Dystrophy Trials at a Glance

8 actively recruiting trials for retinal dystrophy are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Bethesda. Lead sponsors running retinal dystrophy studies include Fondazione G.B. Bietti, IRCCS, Frontera Therapeutics, and Chigenovo Co., Ltd.

Browse retinal dystrophy trials by phase

Treatments under study

About Retinal Dystrophy Clinical Trials

Looking for clinical trials for Retinal Dystrophy? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinal Dystrophy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinal Dystrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Early Phase 1

Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy

Inherited Retinal DystrophyInherited Retinal Disease
Peking Union Medical College Hospital6 enrolled1 locationNCT07656753
Recruiting
Phase 1Phase 2

Oral Metformin for Treatment of ABCA4 Retinopathy

Retinal DegenerationRetinal DystrophyStargardt Disease+1 more
National Eye Institute (NEI)56 enrolled2 locationsNCT04545736
Recruiting
Phase 1Phase 2

Disulfiram for Treatment of Retinal Degeneration

Inherited Retinal Dystrophy Primarily Involving Sensory Retina
University of Washington30 enrolled1 locationNCT05626920
Recruiting
Early Phase 1

A Study of LX107 Gene Therapy in AIPL1-IRD Patients

Retinal Dystrophy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine13 enrolled1 locationNCT07063030
Recruiting
Phase 1Phase 2

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
VeonGen Therapeutics GmbH15 enrolled1 locationNCT07002398
Recruiting
Not Applicable

Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies

Macular EdemaInherited Retinal DystrophyLaser Retinopathy
Fondazione G.B. Bietti, IRCCS10 enrolled1 locationNCT05976139
Recruiting
Phase 3

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Bietti Crystalline Corneoretinal DystrophyBietti Crystalline Dystrophy
Chigenovo Co., Ltd62 enrolled8 locationsNCT06743646
Recruiting
Phase 1Phase 2

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Biallelic RPE65 Mutation-associated Retinal Dystrophy
Frontera Therapeutics9 enrolled1 locationNCT05858983